Clinical Benefits of Olaparib in Mexican Ovarian Cancer Patients With Founder Mutation BRCA1-Del ex9-12

• Published in: Frontiers in genetics 2022-06, Vol.13, p.863956-863956
• Main Authors: Gallardo-Rincón, Dolores, Montes-Servín, Edgar, Alamilla-García, Gabriela, Montes-Servín, Elizabeth, Bahena-González, Antonio, Cetina-Pérez, Lucely, Morales Vásquez, Flavia, Cano-Blanco, Claudia, Coronel-Martínez, Jaime, González-Ibarra, Ernesto, Espinosa-Romero, Raquel, María Alvarez-Gómez, Rosa, Pedroza-Torres, Abraham, Castro-Eguiluz, Denisse
• Format: Article
• Language: English
• Subjects: BRCA mutation; epithelial ovarian cancer; Genetics; large rearrangements; Mexican founder mutation; progression-free survival
• ISSN: 1664-8021; 1664-8021
• DOI: 10.3389/fgene.2022.863956

Background: Ovarian cancer (OC) is gynecologic cancer with the highest mortality rate. It is estimated that 13–17% of ovarian cancers are due to heritable mutations in BRCA1 and BRCA2 . The BRCA1 ( BRCA1 -Del ex9-12) Mexican founder mutation is responsible for 28–35% of the cases with ovarian cancer. The aim was to describe the PFS of OC patients treated with olaparib, emphasizing patients carrying the Mexican founder mutation ( BRCA1 -Del ex9-12). Methods: In this observational study, of 107 patients with BRCA m, 35 patients were treated with olaparib from November 2016 to May 2021 at the Ovarian Cancer Program (COE) of Mexico; patient information was extracted from electronic medical records. Results: Of 311 patients, 107 (34.4%) were with BRCA m; 71.9% (77/107) were with BRCA1 , of which 27.3% (21/77) were with BRCA1 -Del ex9-12, and 28.1% (30/107) were with BRCA2 mutations. Only 35 patients received olaparib treatment, and the median follow-up was 12.87 months. The PFS of BRCA1 -Del ex9-12 was NR (non-reach); however, 73% of the patients received the treatment at 36 vs. 11.59 months (95% CI; 10.43–12.75) in patients with other BRCA m ( p = 0.008). Almost 50% of patients required dose reduction due to toxicity; the most frequent adverse events were hematological in 76.5% and gastrointestinal in 4%. Conclusion: Mexican OC BRCA1 -Del ex9-12 patients treated with olaparib had a significant increase in PFS regardless of the line of treatment compared to other mutations in BRCA .